Characteristics | No. |
---|---|
Median age (range) | 55 (20–71) |
Gender | Â |
  Male | 15 (53.6 %) |
  Female | 13 (46.4 %) |
Hematological disorder | Â |
 Myeloid malignancy |  |
  AML | 3 (10.7 %) |
  MDS overt AML | 6 (21.4 %) |
  MDS | 8 (28.6 %) |
  CML | 1 (3.6 %) |
 Lymphoid malignancy |  |
  ALL | 5 (17.9 %) |
  NHL | 1 (3.6 %) |
  T-PLL | 1 (3.6 %) |
 Others |  |
  Others | 3 (10.7 %) |
Hematopoietic stem cell transplantation | Â |
  CBT | 22 (78.6 %) |
  rPBSCT | 4 (14.3 %) |
  uBMT | 2 (7.1 %) |
Status of the patients | Â |
  Nosocomial infection | 28 (100 %) |
  Severe neutropenia (ANCs <100/pL ) | 28 (100 %) |
  Receipt of beta-lactam in the previous 30 day | 6 (21.4 %) |
Clinical presentation | Â |
  Median body temperature (range) (°C) | 38.6 (37.5-40.6) |
  Acute respiratory distress syndrome | 0 |
  Co-infection | 9 (32.1 %) |
Co-infectious pathogen | Â |
  Staphylococcus epidermidis | 5 |
  Corynebacterium striatum | 2 |
  Enterococcus faecium | 1 |
  Rothia mucilaginosa | 1 |
  Escherichia coli | 1 |
Treatment | Â |
  Cefepime | 26 (92.9 %) |
  Piperacillin/tazobactam | 2 (7.14 %) |
  Empiric VCM administration | 4 (14.3 %) |
Clinical outcome | Â |
  Crude 30-day mortality | 3 (10.7 %) |
  Crude 60-day mortality | 3 (10.7 %) |
Clinical presentation of mono VSB | N = 19 |
  VGS shock syndrome | 5 (26 %) |